Lipantil 200m capsules 200mg №30

Dosage form

capsules

Composition

1 capsule contains: fenofibrate (micronized) 200 mg.

Excipients: sodium lauryl sulfate, lactose, pregelatinized starch, crospovidone, Magnesium stearate, titanium dioxide, ferric oxide, gelatin.

Packing

In the blister 10 capsules. In packing 3 blisters.

Mechanism of action

Lipantil 200 M is a lipid-lowering drug from the group of fibric acid derivatives.

Lowers triglycerides and (to a lesser extent) cholesterol in the blood. It contributes to a decrease in the content of VLDL, LDL (to a lesser extent), an increase in the content of anti-atherogenic HDL. Activates lipoprotein lipase and thereby affects the metabolism of triglycerides; violates the synthesis of fatty xylotes and cholesterol, contributes to the increase in the number of LDL receptors in the liver. Fenofibrate reduces platelet aggregation, reduces elevated levels of fibrinogen in the plasma, can slightly lower the level of glucose in the blood of patients with diabetes, reduces the level of uric acid in the blood.

Indications and usage

- Hypercholesterolemia (type IIa according to Fredrickson's classification).
- Endogenous hypertriglyceridemia (type IV according to Fredrickson's classification).
- Mixed hyperlipidemia (type IIb and III according to Fredrickson's classification).

Contraindications

- Severe abnormal liver function.
- Severe renal dysfunction.
- A history of phototoxic or photoallergic reactions during treatment with fenofibrates or other drugs with similar structure (ketoprofen).
- Combination with other fibrates.
- Congenital galactosemia.
- Lactase deficiency.
- Children's and teenage age up to 18 years.
- Pregnancy.
- Lactation (breastfeeding).

Pregnancy and Breastfeeding

Lipantil 200 M is contraindicated for use during pregnancy and lactation (breastfeeding), due to the lack of sufficient data on the safety of the drug during these periods.

Dosage and administration

Lipantil 200 M is prescribed in 1 capsule / day during one of the main meals. The duration of therapy is established by the attending physician. During therapy, dieting is recommended.

Adverse reactions

Musculoskeletal system: diffuse myalgia, soreness, weakness; rarely - rhabdomyolysis (in some cases, quite a heavy course). When treatment is discontinued, these phenomena are usually reversible.

Gastrointestinal: dyspepsia, transient increase in liver transaminases.

Allergic reactions: skin rash, itching, urticaria, photosensitization. In some cases, after several months of using the drug, photosensitivity reactions may occur in the form of erythema, papules, vesicles, eczematous lesions.

Special notes

In the absence of effect after 3-6 months of taking the drug, concomitant or alternative therapy may be prescribed.

There are reports of the effect of fibrates on muscle tissue, including rare cases of necrosis. These processes occur more often with reduced levels of albumin in the blood plasma. If a patient develops diffuse myalgia, an increase in creatine phosphokinase level (5 times higher than normal), treatment with Lipantil 200 M should be stopped.

In addition, the risk of developing rhabdomyolysis increases while taking the drug with HMG-CoA reductase inhibitors and other fibrates.

Lipantil 200 M contains lactose, so it is contraindicated in congenital galactosemia, lactase deficiency, glucose malabsorption syndrome or galactose.

The combined use of Lipantil 200 M and anticoagulants requires more frequent monitoring of the prothrombin time during the selection of the dose of indirect anticoagulant during treatment with fibrates and within 8 days after their withdrawal.

MAO inhibitors should not be used simultaneously with fenofibrate.

With long-term treatment, it is necessary to control the activity of hepatic transaminases every 3 months in the first year of therapy. In cases of increased activity of AST or ALT enzymes by more than 3 times compared to VGN, the drug is stopped.

Drug interactions

Simultaneous appointment of Lipantil 200 M with other fibrates is contraindicated. increases the risk of rhabdomyolysis.For the same reason, Lipantil 200 M is prescribed with caution in combination with HMG-CoA reductase inhibitors.

The combined use of Lipantil 200 M and indirect anticoagulants may increase their effect and increase the risk of bleeding (control of prothrombin time is necessary).

Overdosage

Symptoms: no specific symptoms noted.
Treatment: if necessary, conduct symptomatic therapy.

Storage conditions

The drug should be stored in a dry place at a temperature of 15 ° to 25 ° C.